IntraVera to launch BruiseMD product at 2009 Natural Products Expo West
GLENDALE, Calif. IntraVera Worldwide will be launching its BruiseMD product at the 2009 Natural Products Expo West, the company announced. BruiseMD will be available in tablets, cream, gel and as an analgesic balm.
The oral version of BruiseMD features natural plant extracts, including pineapple and papaya. The topical versions feature Arnica Montana, a natural ingredient used to heal bruises in combination with topical analgesics for pain relief.
“Every day, nearly 350,000 Americans suffer a new bruise,” stated Raymond Ealy, president and CEO. “There is a pressing consumer need for a product that specifically treats bruises.”
“BruiseMD will speed up the healing process of all three types of bruises: subcutaneous bruises, or those beneath the skin; intramuscular bruises, those within the underlying muscle; and periosteal, or bone bruises, the most severe and painful,” reported James Caillouette, co-founder and board member of IntraVera Worldwide. “Until now, doctors and pharmacists could only recommend the use of pain relievers to treat bruises. These products can decrease bruise pain, but do nothing to heal the bruise.”
Perrigo names VP OTC marketing, consumer health care
ALLEGAN, Mich. Perrigo has promoted Ron Schutt to VP OTC marketing, consumer health care.
Schutt has served Perrigo for 15 years, joining the company in 1993 as a marketing analyst and working through roles in international marketing, pharmaceutical business development and consumer healthcare marketing. Most recently, he served as director of marketing for Perrigo’s U.S. over-the-counter drug business where he managed several of the most successful product launches in the company’s history.
Ron Schutt earned his bachelor’s degree in computer information systems from Ferris State University and his master’s in business administration from Western Michigan University.
Pfizer to manage holdings as small units
NEW YORK Drug maker Pfizer will manage its holdings as small units in a similar fashion to Johnson & Johnson, CEO Jeffrey Kindler told Bloomberg.
Kindler told the news agency that following Pfizer’s acquisition of Wyeth, which caused the world’s biggest drug maker to grow by 50%, he is dividing it into separate units to manage various product divisions, which include prescription drugs, OTC drugs, vitamins and vaccines.